Sertraline in the treatment of panic disorder. A multi-site, double- blind, placebo-controlled, fixed-dose investigation

British Journal of Psychiatry

Volumn 173, Issue JULY, 1998, Pages 54-60

  Londborg, P D ^a   Wolkow, R ^b   Smith, W T ^c   DuBoff, E ^d   England, D ^e   Ferguson, J ^f   Rosenthal, M ^g   Weise, C ^h  

^a Summit Research Network   (United States)

^b PFIZER INC   (United States)

^c Summit Research Network   (United States)

^d Center for Behavioral Medicine   (United States)

^e PeaceHealth Oregon   (United States)

^f Pharmacology Research Corporation   (United States)

^g Behavioral Medical Research   (United States)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

SERTRALINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE INFERTILITY; MULTICENTER STUDY; PANIC; RANDOMIZED CONTROLLED TRIAL;

EID: 0031808125     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.173.1.54     Document Type: Article

References (26)

1. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM-III-R). Washington, DC: APA.
2. Black, D. W., Wesner, R., Bowers, W. et al (1993) A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Archives of General Psychiatry, 50, 44-50.
3. Cassano, G. B., Toni, C., Petracca, A., et al (1994) Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology, 4, 47-53.
4. Den-Boer, J. A., Westenberg, H. G., De Leeuw, A. S., et al (1995) Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine. International Clinical Psychopharmacology, 4, 47-52.
5. Greist, J. H., Chouinard, G., Duboff, E., et al (1995) Double-blind parallel comparison of three doses of sertraline and placebo in outpatients with obsessive compulsive disorder. Archives of General Psychiatry, 52, 289-295.
6. Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub (ADM). Rockville, MD: National Institute for Mental Health.
7. Hamilton, M. (1959) The assessment of anxiety states by rating. British Journal of Medical Psychology, 32, 50-55.
8. _ (1947) Development of a rating scale for primary depressive illness. British Journal of Social Clinical Psychology, 6, 278-296.
9. Hoehn-Saric, R., McLeod, D. R. & Hipsley, P. A. (1993) Effect of fluvoxamine on panic disorder. Journal of Clinical Psychopharmacology, 13, 321-326.
10. Louie, A. K., Lewis, T. B. & Lannon, R. A. (1993) Use of low-dose fluoxetine in major depression and panic disorder. Journal of Clinical Psychiatry, 54, 435-438.
11. Nagy, L. M., Morgan, C. A. III, Southwick, S. M., et al (1993) Open prospective trial of fluoxetine for posttraumatic stress disorder. Journal of Clinical Psychopharmacology, 13, 107-113.
12. Noyes, R. Jr, Garvey, M. J., Cook, B. L., et al (1989) Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. Journal of Clinical Psychiatry, 50, 63-69.
13. Oehrberg, S., Christiansen, P. E., Behnke, K., et al (1995) Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. British Journal of Psychiatry, 167, 374-379.
14. Pecknold, J. C. (1993) Discontinuation reactions to alprazolam in panic disorder. Conference on Panic and Anxiety: A Decade of Progress (1990. Geneva, Switzerland). Journal of Psychiatric Research, 27 (suppl. 1), 155-170.
15. _, Luthe, L., Iny, L., et al (1995) Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study. Psychiatry Neuroscience, 20, 193-198.
16. Pounds, R. (1992) A review of the medical and social consequences of generalized anxiety disorder and panic disorder. Journal of the Louisiana State Medical Society, 144, 479-483.
17. Rosenberg, R. (1993) Drug treatment of panic disorder. Pharmacology and Toxicology, 72, 344-353.
18. Salzman, C. (1993) Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse (Review). Journal of Psychiatric Research, 27 (suppl. 1), 97-100.
19. Sheehan, D. V. (1989) Diagnosis and psychiatry: examination of the psychiatric patient. In Comprehensive Textbook of Psychiatry (5th edn) (eds H. I. Kaplan & B. J. Sadock). Baltimore, MD: Williams and Wilkins.
20. Spitzer, R. L., Williams, J. B. W., Gibbons, M., et al (1990) Structured Clinical Interview for DSM-III-R. Washington, DC: American Psychiatric Press.
21. Svebak, S., Cameron, A. & Levander, S. (1990) Gonazepam and imipramine in the treatment of panic attacks: a double-blind comparison of efficacy and side-effects. Journal of Clinical Psychiatry, 51 (suppl.), 14-17, 50-53.
22. Wade, A., Lepola, U., Koponen, H., et al (1997) The effect of citalopram in panic disorder. British Journal of Psychiatry, 170, 549-553.
23. Weinstein, R. S. (1995) Panic disorder. American Family Physician, 52, 1999-2000, 2055-2063, 2067-2068.
24. Weissman, M. M. (1988) The epidemiology of panic disorder and agoraphobia. American Psychiatric Press Review of Psychiatry (Vol. 7) (eds A. J. Frances & R. E. Hales), pp. 54-66. Washington, DC: American Psychiatric Press.
25. Wolkow, R., Alderman, J., Johnson, H., et al (1996) Sertraline treatment of children and adolescents with obsessive compulsive disorder or depression. X World Congress of Psychiatry Abstracts, 2, 145.
26. Yeragani, V. K., Pohl, R., Balon, R., et al (1992) Imipramine-induced jitteriness and decreased serum iron levels. Neuropsychobiology, 25, 8-10.